Actinogen Medical (ASX: ACW) has released its June 2025 quarterly activities report, highlighting significant progress in its clinical programs and strategic initiatives surrounding Xanamem®, the company’s lead therapeutic compound targeting Alzheimer’s disease (AD) and major depressive disorder (MDD). The June quarter was marked by clinical milestones, manufacturing scale-up, and strengthened financial flexibility through a non-dilutive funding arrangement.

Actinogen Medical Limited (ASX: ACW) is advancing one of the most promising neuroscience drug candidates in the global biotech pipeline. With its novel oral drug Xanamem® (emestedastat), the company is targeting two of the largest and most urgent unmet needs in modern medicine: Alzheimer’s disease (AD) and Major Depressive Disorder (MDD).